J. Gene WANG
Immetas discovers and develops novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The company’s approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases, and anchored in clinical evidence to mitigate development risk. Immetas was founded by J. Gene Wang, MD, PhD, a veteran in discovery and translational drug development in immunology/ inflammation and oncology, and David Sinclair, PhD, Professor of Genetics at Harvard Medical School and a leader in the molecular mechanisms of aging. The lead program in the company’s growing pipeline is focused on engineering bispecific antibodies to modulate inflammation in the tumor microenvironment and overcome resistance to the conventional immune checkpoint therapies. Learn more at www.immetas.com
Immetas Therapeutics
CEOMax Wang
Our mission is very simple: to use immunology to save the lives of the most vulnerable. Whether it’s the young who have yet to develop strong immune systems, the elderly who suffer from waning immune systems, or the immunocompromised whose immune systems are insufficient do to acquired medical conditions or the treatments thereof, Ansun’s mission is to discover and use novel approaches to develop therapies that prevent, treat, and cure some of the world’s most vexing human diseases. This has been our mission since 2003, when Ansun was formed for the purpose of developing a novel approach to treat otherwise untreatable pandemic flu strains (in fact, all flu strains), and it remains our mission today.
Ansun Biopharma
BDMr. Jason Wang
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.